Agreement will bring Alnylam’s proprietary siRNA technology to bear on liver target identified by Novartis researchers Novartis and Alnylam have agreed to collaborate on discovery and development of siRNA-based targeted… Read More
VANCOUVER, BC & SEATTLE, DC- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Mr. Kenneth Galbraith as Chair and Chief Executive Officer… Read More
Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects people all over the world… Read More
VANCOUVER, BC- On December 29, 2021, Her Excellency the Right Honourable Mary Simon, Governor General of Canada, named Acuitas co-founder, Dr. Pieter Cullis, an Officer of the Order of Canada… Read More
Acquisition will strengthen MYND’s psilocybin-assisted medicinal and diagnostics capabilities, adding novel psychedelics for the treatment of dementia, including Alzheimer’s disease. VANCOUVER, BC – Further to news release of October 27, 2021, MYND Life… Read More
